福泰制药宣布美国FDA批准扩大Casgevy®使用范围,适用于两岁及以上镰状细胞病或输血依赖型β地中海贫血患者

美股速递
Jul 02

福泰制药宣布,其基因疗法药物Casgevy®已获得美国食品药品监督管理局的批准,将适用人群扩展至两岁及以上的镰状细胞病或输血依赖型β地中海贫血患者。这一决定标志着该疗法在更广泛的患者群体中,尤其是在年幼儿童中的应用获得了监管认可,有望为更多受这些严重血液疾病困扰的家庭带来新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10